What is the recommended medication for recurrent uncomplicated urinary tract infection?

Recommended Medication for Recurrent UTIs

For acute symptomatic episodes of recurrent UTI, use nitrofurantoin 100 mg twice daily for 5 days as first-line treatment, with fosfomycin 3g single dose or pivmecillinam 400 mg three times daily for 3-5 days as alternatives. 1, 2

Treatment of Acute Episodes

When a woman with recurrent UTI develops acute cystitis symptoms (dysuria, frequency, urgency), treat only the symptomatic infection—never treat asymptomatic bacteriuria, as this increases recurrence risk and antibiotic resistance 1.

First-Line Options (in order of preference):

• Nitrofurantoin monohydrate/macrocrystals: 100 mg twice daily for 5 days

  • Cure rate: 88-93%
  • Narrow spectrum (E. coli, S. saprophyticus)
  • No collateral damage to gut microbiome
  • Low, stable resistance over 50 years 1, 3

• Fosfomycin trometamol: 3g single dose

  • Cure rate: 83-91%
  • Covers VRE and ESBL organisms
  • No collateral damage
  • Currently low resistance 1, 2

• Pivmecillinam: 400 mg three times daily for 3-5 days

  • Good efficacy with benign safety profile
  • Minimal community resistance 1, 2

Alternative Options:

• TMP-SMX: 160/800 mg twice daily for 3 days (only if local E. coli resistance <20%) 1, 2
• Cephalosporins (e.g., cefadroxil 500 mg twice daily for 3 days): Use only if local resistance <20% 2

Newly FDA-Approved Agents (2025):

For multi-drug resistant infections with limited oral options:

• Gepotidacin: New triazaacenaphthylene antibiotic (51% therapeutic success, similar to nitrofurantoin)
• Sulopenem etzadroxil with probenecid: For E. coli, K. pneumoniae, or P. mirabilis when alternatives unavailable 1

Critical Management Principles

Always Obtain Urine Culture When:

• Symptoms don't resolve or recur within 4 weeks of treatment
• Atypical symptoms present
• Suspected pyelonephritis
• Treatment failure 2

If Treatment Fails:

Assume the organism is resistant to the initial agent. Obtain culture with susceptibility testing and retreat with a 7-day regimen using a different antibiotic class 2.

Prevention Strategies (After Acute Treatment)

For women with ≥3 UTIs per year or ≥2 in 6 months, implement prevention strategies only after non-antibiotic options have been tried 2:

Non-Antibiotic Prevention (Try First):

Postmenopausal women:

• Vaginal estrogen replacement (Strong recommendation) 2

All age groups:

• Immunoactive prophylaxis (e.g., OM-89) (Strong recommendation) 2
• Methenamine hippurate (Strong recommendation for women without urinary tract abnormalities) 2

Weaker evidence but reasonable to try:

• Increased fluid intake (premenopausal women)
• Probiotics with proven vaginal flora strains
• Cranberry products (low-quality evidence)
• D-mannose (weak, contradictory evidence) 2

Antibiotic Prophylaxis (When Non-Antibiotic Options Fail):

Use continuous or postcoital prophylaxis (Strong recommendation) 2:

• Nitrofurantoin 50-100 mg daily or post-coital
• TMP-SMX 40/200 mg daily or post-coital
• Fosfomycin 3g every 10 days

Self-start therapy: For compliant patients, provide antibiotics to self-administer at first symptom onset (Strong recommendation) 2

Common Pitfalls to Avoid

1. Never treat asymptomatic bacteriuria: Treatment increases symptomatic recurrence risk (47% vs 13%; RR 3.17) and promotes resistance 1

2. Avoid fluoroquinolones for uncomplicated cystitis: Reserve for pyelonephritis or complicated infections due to collateral damage and resistance concerns 1, 2

3. Don't perform routine imaging: In women <40 years without risk factors, cystoscopy and imaging have low yield 2

4. Don't use short-acting nitrofurantoin formulations: Only monohydrate/macrocrystals formulations are recommended 2

5. Avoid nitrofurantoin, fosfomycin, and pivmecillinam for pyelonephritis: Insufficient data for upper tract infections 2